专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240254214A1 TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab 审中-公开
公开(公告)号：US20240254214A1
公开(公告)日：2024-08-01
申请号：US18360073
申请日：2023-07-27
申请人： REGENXBIO Inc. , The Johns Hopkins University
发明人： Stephen Yoo , Rickey Robert Reinhardt , Sherri Van Everen , Karen Fran Kozarsky , Curran Matthew Simpson , Zhuchun Wu , Peter Anthony Campochiaro , Jikui Shen , Kun Ding
IPC分类号： C07K16/22 , A61F9/00 , A61K9/00 , A61M25/00 , A61M25/01 , A61P27/02 , C12N7/00 , C12N15/86 , A61K39/00 , A61K48/00
CPC分类号： C07K16/22 , A61F9/0017 , A61K9/0019 , A61K9/0048 , A61M25/0084 , A61M25/0194 , A61P27/02 , C12N7/00 , C12N15/86 , A61K2039/505 , A61K48/00 , A61M2025/0089 , A61M2210/0612 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C12N2750/14143 , C12N2750/14171
摘要： Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”) —such as, e.g., a fully human-glycosylated (HuGly) anti-h VEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

2. 发明申请

US20150141359A1 Controlled Release Formulations for the Delivery of HIF-1 Inhibitors 有权
标题翻译：用于输送HIF-1抑制剂的控制释放制剂
公开(公告)号：US20150141359A1
公开(公告)日：2015-05-21
申请号：US14599853
申请日：2015-01-19
申请人： The Johns Hopkins University
发明人： Justin Scot Hanes , Peter Anthony Campochiaro , Jie Fu
IPC分类号： A61K47/48 , A61K9/00 , A61K31/704
CPC分类号： A61K47/60 , A61K9/0048 , A61K9/14 , A61K9/16 , A61K31/704 , A61K47/50 , A61K47/59 , A61K47/6907
摘要： Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD.
摘要翻译：提供用于递送一种或多种HIF-1抑制剂的控制释放剂量制剂。控制释放制剂含有一种或多种与聚合物载体共轭或分散在其中的HIF-1抑制剂。一种或多种HIF-1抑制剂可以分散或包封在聚合物基质中。在一些实施方案中，一种或多种HIF-1抑制剂与聚合物共价结合，形成聚合物 - 药物缀合物。聚合物载体可以形成植入物，微粒，纳米颗粒或其组合。受控释放的HIF-1制剂通过在长时间内释放低水平的一种或多种HIF-1抑制剂和/或HIF-1抑制剂缀合物来提供延长的治疗益处，同时降低副作用。控制释放剂量制剂可用于治疗或预防与血管形成相关的患者（包括癌症，肥胖症和眼部疾病如湿性AMD）中的疾病或病症。

3. 发明申请

US20200277364A1 TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab 审中-公开
公开(公告)号：US20200277364A1
公开(公告)日：2020-09-03
申请号：US16645877
申请日：2018-09-26
申请人： REGENXBIO Inc. , The Johns Hopkins University
发明人： Stephen Yoo , Rickey Robert Reinhardt , Sherri Van Everen , Karen Fran Kozarsky , Curran Matthew Simpson , Zhuchun Wu , Peter Anthony Campochiaro , Jikui Shen , Kun Ding
IPC分类号： C07K16/22 , A61K9/00 , A61P27/02 , C12N15/86 , C12N7/00 , A61F9/00 , A61M25/01 , A61M25/00
摘要： Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

4. 发明申请

US20130274217A1 Controlled Release Formulations for the Delivery of HIF-1 Inhibitors 有权
公开(公告)号：US20130274217A1
公开(公告)日：2013-10-17
申请号：US13797506
申请日：2013-03-12
申请人： The Johns Hopkins University
发明人： Justin Scot Hanes , Peter Anthony Campochiaro , Jie Fu
IPC分类号： A61K47/48 , A61K9/00
CPC分类号： A61K47/60 , A61K9/0048 , A61K9/14 , A61K9/16 , A61K31/704 , A61K47/50 , A61K47/59 , A61K47/6907
摘要： Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD.

5. 发明授权

US09950072B2 Controlled release formulations for the delivery of HIF-1 inhibitors 有权
公开(公告)号：US09950072B2
公开(公告)日：2018-04-24
申请号：US14599853
申请日：2015-01-19
申请人： The Johns Hopkins University
发明人： Justin Scot Hanes , Peter Anthony Campochiaro , Jie Fu
IPC分类号： A61K31/704 , A61K9/14 , A61K9/16 , A61K47/50 , A61K47/48 , A61K9/00
CPC分类号： A61K47/60 , A61K9/0048 , A61K9/14 , A61K9/16 , A61K31/704 , A61K47/50 , A61K47/59 , A61K47/6907
摘要： Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD.

6. 发明授权

US08962577B2 Controlled release formulations for the delivery of HIF-1 inhibitors 有权
标题翻译：用于递送HIF-1抑制剂的控制释放制剂
公开(公告)号：US08962577B2
公开(公告)日：2015-02-24
申请号：US13797506
申请日：2013-03-12
申请人： The Johns Hopkins University
发明人： Justin Scot Hanes , Peter Anthony Campochiaro , Jie Fu
IPC分类号： A61K31/70 , C07H15/24 , A61K47/48 , A61K9/00
CPC分类号： A61K47/60 , A61K9/0048 , A61K9/14 , A61K9/16 , A61K31/704 , A61K47/50 , A61K47/59 , A61K47/6907
摘要： Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD.
摘要翻译：提供用于递送一种或多种HIF-1抑制剂的控制释放剂量制剂。控制释放制剂含有一种或多种与聚合物载体共轭或分散在其中的HIF-1抑制剂。一种或多种HIF-1抑制剂可以分散或包封在聚合物基质中。在一些实施方案中，一种或多种HIF-1抑制剂与聚合物共价结合，形成聚合物 - 药物缀合物。聚合物载体可以形成植入物，微粒，纳米颗粒或其组合。受控释放的HIF-1制剂通过在长时间内释放低水平的一种或多种HIF-1抑制剂和/或HIF-1抑制剂缀合物来提供延长的治疗益处，同时降低副作用。控制释放剂量制剂可用于治疗或预防与血管形成相关的患者（包括癌症，肥胖症和眼部疾病如湿性AMD）中的疾病或病症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式